Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Relinde I. Y. Lieverse*, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David PasquierPierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number557
Number of pages10
JournalBMC Cancer
Volume20
Issue number1
DOIs
Publication statusPublished - 15 Jun 2020

Keywords

  • Immunotherapy
  • L19-IL2
  • Anti-PD-L1
  • Anti-PD-1
  • Radiotherapy
  • SABR
  • Phase 2
  • NSCLC
  • Stage IV
  • Multicentre
  • CELL LUNG-CANCER
  • LOCAL CONSOLIDATIVE THERAPY
  • ED-B FIBRONECTIN
  • EXTRA-DOMAIN-B
  • IMMUNOCYTOKINE L19-IL2
  • MAINTENANCE THERAPY
  • RADIATION-THERAPY
  • DOSE-ESCALATION
  • SOLID TUMORS
  • MARKER

Cite this